[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561993":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":17,"responsibleParty":35,"collaborators":38,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":7,"enrollmentInfo":55,"targetDuration":7,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"IRCCS San Raffaele","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Luigi Di Filippo, medical doctor","CONTACT","+39 0226435062","difilippo.luigi@hsr.it",{"name":15,"role":11,"phone":12,"phoneExt":7,"email":16},"Gabriela Felipe, clinical research nurse","felipe.gabriela@hsr.it",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Andrea Giustina","RECRUITING","Milan","20132","Italy","IT",{"type":26,"coordinates":27},"Point",[28,29],9.18951,45.46427,{"lat":29,"lon":28},[32],{"name":33,"role":11,"phone":34,"phoneExt":7,"email":16},"Gabriela Felipe, nurse","0226435062",{"type":36,"investigatorFullName":19,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Professor of Endocrinology",[39,41,43],{"name":40,"class":6},"University of Turin, Italy",{"name":42,"class":6},"University of Padova",{"name":44,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","100561993","the-rapid-switch-from-1st-generation-somatostatin-analogues-to-pasireotide-in-acromegaly-100561993",false,"NCT06597383","The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly","The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly ( RAPSODIA )","RAPSODIA","Inclusion Criteria:\n\n* Adult men and women (age ≥ 18 years) affected by acromegaly, including those of childbearing age\n* Patients inadequately controlled with first generation somatostatin analogues (GH ≥1 μg\u002FL and IGF-1 \\>1.3×ULN)\n* Second line medical treatment (Pasireotide; Pegvisomant only; combination Pegvisomant + 1st generation SSA) after use of first-line medical treatment\n* At least 12 months of follow up during 2nd line therapy\n* Signature of the informed consent to the study\n\nExclusion Criteria:\n\n* age ≤18 years\n* Pregnant and\u002For breastfeeding women\n* Patients unable to understand and sign the Informed Consent","ALL","18 Years",{"count":56,"type":57},100,"ESTIMATED","OBSERVATIONAL","This is an observational, retrospective, national multicenter study aimed to evaluate the impact and efficacy of Time To Switch (TTS) from first-line to second-line medical therapy in Acromegaly.",[61],"Acromegaly",[63,64,65],"somatostatin analogues","pasireotide","pegvisomant","2024-09-11",{"date":68,"type":69},"2024-09-19","ACTUAL",{"date":71,"type":69},"2023-11-24",{"date":73,"type":57},"2024-11",{"name":5,"class":6},1]